Royalty Report: Medical, Supply, Pain – Collection: 58867

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Medical
  • Supply
  • Pain
  • Therapeutic
  • Wound Care
  • Nerve
  • Device
  • Diagnostic
  • Orthopedic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 58867

License Grant
The Licensee entered into an exclusive license agreement with the Licensors for the use of their patent application for the method of producing autologous PRP to treat neuropathy.
License Property
The patent application is for a method of producing autologous PRP to treat neuropathy.  Neuropathy is a nerve disease causing numbness and pain.  Our products utilize Platelet rich plasma (PRP), a blood plasma derived product, which typically contains an elevated level of platelets and growth factors (at least four to eight times) than normal blood concentration. PRP appears to have beneficial effects for tendon, ligament or muscle injuries, maxillofacial therapies, dentistry, cosmetics, wound healing, cardiothoracic surgery, ear–nose–throat surgery, neurosurgery, urology, and ophthalmology.

Platelet-rich plasma (PRP) is blood plasma that has been enriched with platelets.

Field of Use
The Licensee will have exclusive rights to utilize this application in connection with the manufacture and sale of its neuropathy treatment products. The Licensee is currently developing products for treating peripheral neuropathy, hair loss and facial rejuvenation using platelet-rich plasma. As a concentrated source of autologous platelets, PRP contains (and releases through degranulation) several different growth factors and other cytokines that stimulate healing of bone and soft tissue, and can also be used as a treatment for hair regrowth. These products are not yet commercially available.

IPSCIO Record ID: 26656

License Grant
A U.S. pharma has granted the worldwide rights to a U.S business unit of an Italian company the Knighton patent for all applications relating to the use of autologous platelet releasate therapies for healing purposes (wound-healing and tissue repair therapies).  U.S. Patent No. 5,165,938 entitled Wound Healing Agents.
License Property
5,165,938 A process for treating a wound of a live animal which comprises applying over the wound an effective amount of a treating composition containing the materials released by platelets during the platelet release reaction and facilitating healing of the wound.
Field of Use
Licensed Fields means any and all fields of use.

IPSCIO Record ID: 5492

License Grant
LICENSOR hereby grants to LICENSEE, to the extent of the LICENSED FIELD and LICENSED TERRITORY, a license under PATENTS, to fully practice PATENTS, including the right to make, use, offer for sale, sell and import PRODUCTS and promote the methods and compositions recited in the claims of PATENTS using PRODUCTS in the LICENSED FIELD.
License Property
The U.S. and foreign issued patents relates to platelet-based growth factors (used in platelet rich plasma gel used in wound care in the specific field of use covering diagnostic and therapeutic spinal, neurosurgery and orthopedic surgery. U.S. Patent No. 5,165,938 entitled “Wound Healing Agents,” issued 11/24/92.
Field of Use
SCHEDULE OF PRODUCTS
SEPARATORS
2760-40-101       Disposable Processing Kit – Single
2760-40-102       Disposable Processing Kit – Double

Disposable Processing Kits contain the items required for containing blood during processing in the centrifuge

CAPITAL
2760-40-000       Centrifuge
2760-40-310       Centrifuge and Cart Assembly

APPLICATORS/ MIXERS
2760-40-200       Applicator Kit

IPSCIO Record ID: 301064

License Grant
Licensor grants a non- transferable, exclusive, license for the APIC System, without the right to sell or grant sublicenses without the expressed written consent of Licensor, and such consent may not be unreasonably  withheld or delayed unless the new licensee is unable or ill-equipped to perform Commercially Reasonable Efforts due to reasons including, but not limited to, an insufficient business plan, inexperienced management, ongoing legal disputes, etc.

Licensor grants a non-transferable, non-exclusive, personal license to use the Marks and other commercial symbols of Licensor related only to the APIC PRP System, designated by Licensor from time-to- time, only in connection with the promotion, marketing, advertising and sale of APIC for Veterinary Applications.

License Property
The proprietary technology is for diagnosing and treating joint and back pain in animals.

APIC System and APIC shall mean the APIC PRP System and all associated products, whether or not designed, manufactured, patented, produced by or for Licensor, including but not limited to the APIC Processing Kit, the APIC Pump, and the APIC Centrifuge (the APIC Pump and the APIC Centrifuge known collectively as the APIC Equipment), the APIC Mini, or any pump system or centrifuge designed or modified to work in conjunction with the APIC Kits and sold by Licensee for the purpose of producing Autologous Therapeutic Products, and any other related products used in conjunction with the APIC System including stands, carts, or other disposable products.

APIC Kit shall mean the disposable kits for the collection and processing of Autologous Therapeutic Products, which includes the APIC Mini System.

APIC New Products shall mean for autologous therapies an improvement, new development, modification or enhancement to the APIC System for Veterinary Applications that is developed by Licensor and is used for Veterinary Applications, including but not limited to the APIC Mini System.

“The Cytonics Autologous Platelet Integrated Concentrate (APIC-PRP) is indicated for the rapid preparation of autologous platelet rich plasma from a small sample of blood at the patient's point of care. The platelet rich plasma is mixed with autograft and/or allograft bone prior to application to a bony defect for improving bone graft handling characteristics.”

Field of Use
Therapeutic Field shall mean the treatment of Veterinary Applications in all species of animals.   Veterinary Applications shall mean all conditions, maladies, and diagnosis involving pain, inflammation, or degradation of joints and spinal discs in all species of animals.

IPSCIO Record ID: 40994

License Grant
Licensor grants to Licensee (A) an exclusive, irrevocable, worldwide, sub-licensable, transferable license to the Patents used in the Technology to research, develop, make, have made, use, sell, offer for sale, have sold, distribute and have distributed, import and have imported, the Products and New Products within the Exclusive Field of Use and (B) a non-exclusive, irrevocable, worldwide, sub-licensable, transferable license to the Patents used in the Technology to research, develop, make, have made, use, sell, offer for sale, have sold, distribute and have distributed, import and have imported, the Products and New Products within the Non-Exclusive Field of Use.
License Property
Technology means the Intellectual Property Rights and Product Registration Rights required to make, use, and sell the Product Line.  Product Line means the Angel® Concentrated Platelet System product line.  The product line represents point of care technologies for the safe and efficient separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates. The Company currently has two distinct platelet rich plasma (“PRP”) devices, one of which is the Angel® concentrated Platelet Rich Plasma (“cPRP”) System for orthopedics markets.
Field of Use
This agreements relates to the separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates for orthopedics markets.

IPSCIO Record ID: 26682

License Grant
Licensor hereby grants to Licensee for the a non-exclusive, royalty-bearing license to manufacture, have made, use, import, sell, promote, market, offer for sale, or otherwise transfer Platelet Products, Activated Platelet Gel Services and Experimental Platelet Gel Therapies for use in practicing or involving the practice of processes covered by one or more claims of the Licensed Patent in any field of use.
License Property
The controversy between the Parties based upon Licensee's manufacture, use, marketing, offer to sell, and/or sale of products alleged to infringe U.S. Patent No. 5,165,938.

Activated Platelet Gel Therapies are defined as methods of treating damaged tissues and/or wounds using topical compositions containing platelets activated by adding thrombin or another biologic release agent, or containing substances released from platelets after activation by adding thrombin or another biologic release agent.

Experimental Platelet Gel Therapies are defined as methods of treating damaged tissues and/or wounds using topical compositions containing platelets activated by locally present thrombin or another biologic release agent, or containing substances released from platelets after activation by locally present thrombin or another biologic release agent, i.e., without adding thrombin or another biologic release agent.

Schedule of SafeBlood Branded Single Use Disposable Kit Products
Item Description

Manufacturer Number

SafeBlood Graft Kit
                    
SBG KitSB101 / W

SafeBlood Graft Kit

SBG KitSB101 / W 1

SafeBlood Graft Kit

SBG KitSB102 / W

SafeBlood Graft Kit

SBG KitSB201 / W

SafeBlood Graft Kit

SBG Kit SB 103

SafeBlood Graft Kit 800-1001A(1)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(2)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(3)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(4)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(5)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(6)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(7)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A

BIOMETGPS 800-1001A

GPS Counter Balance

BIOMETGPS 800-0508

Schedule of SafeBlood Branded Single Use Disposable Component Products

Item Description

Manufacturer Number

SBG Graft Activator
    
CD SBG-1005

Ratio Procedure kit

Micromedics SA-4400

Blending Connector

Micromedics SA-3674

Single Spray Tip

Micromedics SA-3671

Dual Spray Applicator Tip

Micromedics SA-3660

Dual Tip

Micromedics SA-0205

Schedule of SafeBlood Branded Capital Equipment Products
Item Description

Manufacturer Number

GPS Centrifuge 120 Volt 50-60HZ
    
GPS – 7426

IPSCIO Record ID: 27075

License Grant
The Company has the exclusive right to utilize the process to make and apply AuTolo-Gel TM and full and exclusive right, title and interest, both national and international, to certain patent applications identified as the Patent Cooperation Treaty Application entitled Enriched Platelet Wound Healant the Licensor, an individual.
License Property
The AuTolo-Cure TM system is based upon the use of a process developed for the application of an autologous platelet-rich concentrated gel to chronic wounds. The process removes platelets from the individual, applies a process developed by Worden to create AuTolo-Gel TM and then applies the gel to the wound.  By using the patient’s own platelets to create the gel, the system is an autologous process.
Field of Use
The Company intends to market and sell its proprietary system for the treatment of chronic wounds presently identified by the servicemark, AuTolo-Cure TM ('the AuTolo-Cure TM system').   AuTolo(TM)-Gel is a proprietary autologous tissue coagulum for treating chronic nonhealing wounds such as; diabetic foot ulcers, venous stasis wounds and pressure ulcers.

IPSCIO Record ID: 372628

License Grant
These Parties have entered into a certain Asset Purchase Agreement.

For the License, Licensor grants a worldwide license under the Licensed Technology to make, have made, use, offer to sell, sell, and otherwise commercialize Licensed Products, solely within the Field of Use.

For the Right to Grant Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to make, have made, use, offer to sell, sell, and otherwise commercialize Licensed Products within the Field of Use.

License Property
The patents include
Platelet-Derived Growth Factor Compositions and Methods of Use Thereof;
Maxillofacial Bone Augmentation Using rhPDGF-BB and a Biocompatible Matrix;
Compositions and Methods for Repairing Cartilage Defects;
Compositions and Methods for Treating Bone;
Prevention and Treatment for Osteonecrosis and Osteonecrosis of the Jaw;
Methods and Compositions for Treating the Vertebral Column; and,
Compositions and Methods for Treating Rotator Cuff Injuries.

Licensor has certain assets related to the orofacial therapeutic business.

rhPDGF means recombinant human platelet derived growth factor.

Licensed Products means any product with application within the Field of Use that Licensor and/or Licensee develops or has developed which is covered by the Licensed Technology, developed through the use of a process which is covered by the Licensed Technology, or could not be manufactured, used or sold without the incorporation or use in whole or in part of some or all of the Licensed Technology, including, but not limited to
—  any Growth Factor product, including GEM 21S, GEM ONJ, GEM 22A, and a GEM OS2-like product for application within the Field of Use, including Growth Factors alone, combinations of Growth Factors, and combinations of Growth Factors with non-Growth Factor products, and any component thereof, for which commercialization thereof is not subject to a third party license agreement that Licensor enters into after the Closing of the Asset Purchase Agreement;
—  any device, e.g., bone matrix material, implant and/or related product, for which the commercialization thereof is not subject to a third party license agreement that Licensor enters into after the Closing of the Asset Purchase Agreement.

Field of Use
The Field of Use means all applications above the neck in humans and all veterinary applications. For the avoidance of doubt, Field of Use in humans does not include central nervous system diseases such as multiple sclerosis, nerve regeneration or extraoral dermal or epidermal tissue, except that oral indications, such as cleft lip and palate, that traverse the intraoral-extraoral boundary, are not excluded.

IPSCIO Record ID: 306475

License Grant
For the Technology License, Licensor grants a non-transferable, exclusive, personal license for the APIC System and FACT diagnostic, without the right to sell or grant sublicenses, except sublicenses to Licensee’s Affiliates, distributors and one or more Third Party Suppliers engaged by Licensee to assemble, produce, and package APIC Kits or APIC Equipment), solely to assemble and have assembled the APIC System for the purpose of marketing and distributing the APIC System for Human Applications.

For the Trademark License, Licensor grants a non-transferable, non-exclusive, personal license to use the Marks and other commercial symbols of Licensor designated by Licensor from time-to-time, only in connection with the promotion, marketing, advertising and sale of APIC and FACT for Human Applications.

License Property
APIC System and APIC shall mean the APIC PRP System and all associated products, whether or not designed, manufactured, patented, produced by or for Licensor, including but not limited to the APIC Processing Kit (APIC Kits), the APIC Pump, and the APIC Centrifuge (the APIC Pump and the APIC Centrifuge known collectively as the APIC Equipment) or any pump system or centrifuge designed or modified to work in conjunction with the APIC Kits and sold by Licensee for the purpose of producing Autologous Therapeutic Products, and any other related products used in conjunction with the APIC System including stands, carts, or other disposable products.

APIC Kit shall mean the disposable kits manufactured by Licensor, Licensee, their suppliers and Affiliates sold to Customers for the collection and processing of Autologous Therapeutic Products.

FACT shall mean the Fibronectin-Aggrecan Complex Test.

Licensor is a development stage research company dedicated to developing therapeutics based on the naturally-occurring protease inhibitor alpha-2-macroglobulin (A2M), a blood serum protein that has known cartilage-protecting effects and could potentially serve as a treatment for osteoarthritis.  Licensor develops, markets, and distributes analytic tools used to detect biomarkers associated with certain diseases referred to as assays, therapeutic drugs, and related instruments and disposables related to musculoskeletal diseases.

Field of Use
The FACT diagnostic product is currently sold to physicians nationwide, and is used to assess the extent of cartilage damage in patients and determine the appropriate course of treatment.

The FACT product is often used in conjunction with our Autologous Platelet Integrated Concentrate (“APIC-PRP”) therapy for osteoarthritis and joint pain. The APIC-PRP system is predicated on Platelet Rich Plasma (PRP) technology, which concentrates the plasma cells found in blood and is injected into joints that are painful and inflamed. The APIC-PRP system differs from PRP in that it selectively concentrates alpha-2-macroglobulin (A2M) while removing other harmful, pro-inflammatory blood proteins. A2M is a well-known blood serum protease inhibitor which prevents the proteins that “digest” cartilage from having a deleterious effect.

Licensee’s appointment is limited to the marketing and sale of the APIC System to Customers for Human Applications in the Territory and in the Therapeutic Field.  Human Applications shall mean all conditions, maladies, and diagnosis involving pain, inflammation, or degradation of joints and spinal discs in humans..

IPSCIO Record ID: 301063

License Grant
Licensor appoints Licensee as the exclusive distributor of the APIC System, in the Territory and in the Therapeutic Field, to market and distribute the APIC System, and all Related Products to Customers for Orthopedic Applications.

Licensor grants a non-transferable, exclusive, personal license for the APIC System, without the right to sell or grant sublicenses, solely to assemble and have assembled the APIC System for the purpose of marketing and distributing the APIC System for Orthopedic Applications.

Licensor grants a non-transferable, non-exclusive, personal license to use the Marks and other commercial symbols of Licensor designated by Licensor from time-to-time, only in connection with the promotion, marketing, advertising and sale of APIC for Orthopedic Applications.

Licensor grants an option to negotiate for a commercial license to make, have made, use, sell, offer to sell, market, and distribute the APIC Mini System.

Licensor grants an option to negotiate for a commercial license to make, have made, use, sell, offer to sell, market, and distribute the APIC Cell Free System.

Licensor grants an option to negotiate for the exclusive rights to sell, market, and distribute the APIC System in any country or in countries outside the USA, the APIC International Rights.

License Property
The license property is proprietary technology for diagnosing and treating osteoarthritis and other causes of joint and back pain.

APIC Kit shall mean the disposable kits manufactured by Licensor, Licensee, their suppliers and Affiliates sold to Customers for the collection and processing of Autologous Therapeutic Products.

APIC New Product shall mean an improvement, new development, modification or enhancement to the APIC System for Orthopedic Applications that is developed by Licensor and is used for Orthopedic Applications, including but not limited to the APIC Mini System and the APIC Cell Free System.

“The Cytonics Autologous Platelet Integrated Concentrate (APIC-PRP) is indicated for the rapid preparation of autologous platelet rich plasma from a small sample of blood at the patient's point of care. The platelet rich plasma is mixed with autograft and/or allograft bone prior to application to a bony defect for improving bone graft handling characteristics.”

Field of Use
The therapeutic Field shall mean the treatment of orthopedic conditions in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.